Jefferies Financial Group Inc. Purchases New Position in Sarepta Therapeutics, Inc. $SRPT

Jefferies Financial Group Inc. acquired a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 190,200 shares of the biotechnology company’s stock, valued at approximately $3,418,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. iSAM Funds UK Ltd bought a new position in Sarepta Therapeutics in the 3rd quarter valued at $25,000. Kestra Advisory Services LLC acquired a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at $25,000. Meeder Asset Management Inc. bought a new position in shares of Sarepta Therapeutics in the second quarter valued at about $27,000. Ancora Advisors LLC lifted its position in Sarepta Therapeutics by 200.0% during the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after buying an additional 1,000 shares in the last quarter. Finally, Allworth Financial LP grew its holdings in Sarepta Therapeutics by 2,098.8% during the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 1,721 shares during the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Stock Down 3.4%

NASDAQ:SRPT opened at $20.86 on Friday. The company has a quick ratio of 2.62, a current ratio of 4.42 and a debt-to-equity ratio of 0.55. Sarepta Therapeutics, Inc. has a 12-month low of $14.68 and a 12-month high of $25.32. The stock’s fifty day simple moving average is $17.73 and its 200-day simple moving average is $18.32. The firm has a market capitalization of $2.20 billion, a P/E ratio of -7.19, a P/E/G ratio of 0.32 and a beta of 0.23.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.42. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%.The firm had revenue of $401.25 million for the quarter, compared to analyst estimates of $366.39 million. During the same quarter in the prior year, the firm posted $2.02 earnings per share. The company’s quarterly revenue was down 34.3% on a year-over-year basis. Equities research analysts expect that Sarepta Therapeutics, Inc. will post 3.43 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have weighed in on SRPT. Zacks Research raised shares of Sarepta Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Wolfe Research raised Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price objective on the stock in a report on Thursday, July 9th. HC Wainwright reiterated a “buy” rating on shares of Sarepta Therapeutics in a research report on Tuesday, July 28th. Wall Street Zen downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Piper Sandler lowered their price objective on Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating for the company in a research report on Thursday, July 9th. Nine research analysts have rated the stock with a Buy rating, six have given a Hold rating and five have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Sarepta Therapeutics has an average rating of “Hold” and a consensus target price of $25.06.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.